Frontiers
Browse
Image_1_Non-targeted Metabolomics Profiling of Plasma Samples From Patients With Major Depressive Disorder.TIF (291.29 kB)

Image_1_Non-targeted Metabolomics Profiling of Plasma Samples From Patients With Major Depressive Disorder.TIF

Download (291.29 kB)
figure
posted on 2022-02-21, 04:23 authored by Zhonghao Wu, Heming Yu, Yu Tian, Yue Wang, Yong He, Tianlan Lan, Yan Li, Mengge Bai, Xiangyu Chen, Zhi Chen, Ping Ji, Hongmei Zhang, Xin Jin, Jinlin Song, Ke Cheng, Peng Xie
Background

Major depressive disorder (MDD) is a neuropsychiatric disorder caused by multiple factors. Although there are clear guidelines for the diagnosis of MDD, the direct and objective diagnostic methods remain inadequate thus far.

Methods

This study aims to discover peripheral biomarkers in patients with MDD and promote the diagnosis of MDD. Plasma samples of healthy controls (HCs, n = 52) and patients with MDD (n = 38) were collected, and then, metabolism analysis was performed using ultrahigh-performance liquid chromatography–tandem mass spectrometry (LC–MS/MS). Heatmap analysis was performed to identify the different metabolites. Meanwhile, receiver operating characteristic (ROC) curves of these differential metabolites were generated.

Results

Six differential metabolites were found by LC–MS/MS analysis. Three of these were increased, including L-aspartic acid (Asp), diethanolamine, and alanine. Three were decreased, including O-acetyl-L-carnitine (LAC), cystine, and fumarate. In addition, LAC, Asp, fumarate, and alanine showed large areas under the curve (AUCs) by ROC analysis.

Conclusion

The study explored differences in peripheral blood between depressed patients and HCs. These results indicated that differential metabolites with large AUCs may have the potential to be promising biomarkers for the diagnosis of MDD.

History

Usage metrics

    Frontiers in Psychiatry

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC